We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Eletriptan.
- Authors
Bardsley-Elliot, A.; Noble, S.
- Abstract
▴ Eletriptan is a new serotonin 5-HT receptor agonist developed for the treatment of acute migraine attacks. ▴ The increased lipophilicity of eletriptan provides rapid absorption, and improved oral bioavailability over that of sumatriptan. ▴ In animal studies, eletriptan effectively decreased carotid anastomotic blood flow, but exhibited a lower potential than sumatriptan to constrict coronary and femoral blood flow in a canine assay of potential adverse cardiovascular effects. ▴ Eletriptan was effective in reducing migraine pain from severe or moderate to mild or none within 2 hours of administration of a single oral 40 or 80mg dose in a large, multicentre, double-blind placebo-controlled trial (n = 1151). ▴ In a double-blind, placebo-controlled comparative study, eletriptan (80mg, single oral dose) was significantly more effective than sumatriptan (100mg, single oral dose) in reducing headache pain at both 1 and 2 hours after administration (n = 692). ▴ Eletriptan is generally well tolerated. The most commonly reported adverse events were asthenia, somnolence, dizziness and nausea; these were typically mild and transient in nature.
- Publication
CNS Drugs, 1999, Vol 12, Issue 4, p325
- ISSN
1172-7047
- Publication type
Academic Journal
- DOI
10.2165/00023210-199912040-00006